Mammalian-based Platform Accounts for 70% Share
Owing to their greater efficiency versus microbial-based cell culture, mammalian-based platforms such as Chinese hamster ovary (CHO) continue to remain a better choice for the production of biopharmaceuticals. With its adoption rate growing robustly, the revenue share of mammalian-based cell culture will follow an upward trajectory during the opportune time.
By 2027, the application of mammalian-based platforms is likely to register over US$ 10 Bn in value. Moreover, demand growth of microbial-based platforms is expected to decline in the near future, due to high risks of cell contamination in micro-environment culture vessels.
North America in Vanguard, APEJ to Exhibit Market Attractiveness
Accounting for a collective share of around 60%, the biopharmaceutical contract manufacturing markets in North America and Western Europe are currently capturing significant portions of investments. While these developed regional markets are defining manufacturers’ bottom lines, accelerated adoption of biopharmaceutical contract manufacturing in Asia Pacific (Excluding Japan) is resulting in realignment of strategies. Cheaper manufacturing costs in this developing region are attracting various multinational biopharma companies for further R&D projects in biologic drugs.
Local Biologics Production to Set High Hopes
The current status of biologics development is influencing governments in developed and developing countries to significantly invest in advanced healthcare infrastructure. This is auguring well for the biopharmaceutical industry in these regions, which is further boosting the growth of the biopharmaceutical contract manufacturing market. The Government of Brazil, in a bid to improve overall biologics capacity, especially biosimilars and follow on biologics, has carved out a significant share of its healthcare expenditure for the local production of biologics. This increasing focus on enhancing domestic capacity would be an attention-grabbing factor for biopharmaceutical contract manufacturing organizations.
How Growth will Unfold
By capturing nearly half of the total market revenue, monoclonal antibodies (MaB) will continue to engage market players through 2029. The benefits of high specificity and clinical efficiency in treating chronic diseases, including cancer and other autoimmune diseases, are boosting the popularity of MaBs in the biopharmaceutical space. Although their exorbitant production costs are limiting their applicability in treating a broad array of infectious diseases, their use in laboratory and clinical settings is creating room for further novel and cost-efficient innovation such as plantibodies.
FREQUENTLY ASKED QUESTIONS ABOUT BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
How will the biopharmaceutical contract manufacturing market fare in the future?
Demand for biopharmaceutical contract manufacturing is poised to increase at a staggering CAGR of 10% over the forecast period. An increase in the focus on better and safer transportation and rise in the demand for pallets from food and transportation industries are expected to surge market growth.
Will the high capital investment of biologics manufacturing units affect the future trajectory of the market?
Yes, due to the involvement of high capital investment in the establishment of biologics manufacturing units, biopharmaceutical players are focusing on outsourcing bio-manufacturing. This has elevated the demand for CMOs in the biopharmaceutical contract manufacturing market space.
Which application area holds potential growth opportunities for players?
Demand from commercial biologics contract manufacturing holds the largest market share. The presence of a large number of FDA-approved biologics in the market is majorly driven due to the massive success of biopharmaceutical contract manufacturing.
What is the degree of competition in the biopharmaceutical contract manufacturing market?
Companies in the biopharmaceutical contract manufacturing market are making strategies of acquisition and collaborations to expand their business. Some of the companies are even involved in inorganic growth strategies, cross-selling, and encouraging longer-term relationships through increasingly comprehensive offerings.
Which region is at the forefront of the demand for biopharmaceutical contract manufacturing?
North America is poised to be the leading biopharmaceutical contract manufacturing market over the next decade. However, the reactor capacities of companies in the market are expected to move slightly from North America to Asia, due to rapid expansion in China, Singapore, and Korea, and government incentives and tax advantages, over the forecast period.
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET TAXONOMY
FMI’s study on the biopharmaceutical contract manufacturing market offers information divided into five important segments - platform, product type, application, therapeutic area, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Platform
- Mammalian-based
- Microbial-based
Product Type
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Insulin
- Interferons
- Growth Factors
- Others
Application
- Clinical
- Commercial
Therapeutic Area
- Autoimmune Disease
- Oncology
- Metabolic Disease
- Opthalmology
- Cardiovascular Disease
- Infectious Disease
- Neurology
- Respiratory Disorder
- Others
Region
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- JAPAN
- Middle East and Africa
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports